Clinicopathologic Characteristics of Late Acute Antibody-mediated Rejection in Pediatric Liver Transplantation

Background. An early and accurate diagnosis of liver antibody-mediated rejection (AMR) followed by timely intervention is important for clinical management but remains challenging. The aim of this study was to assess the clinicopathologic characteristics and outcomes of late acute AMR in pediatric liver transplantation recipients. Methods. We performed a retrospective review of 739 ABO-identical/compatible allograft liver biopsies from 199 pediatric transplantation recipients. Results. Based on Banff 2016 AMR criteria, 3 recipients fulfilled the criteria for definite for late acute AMR, 2 met the criteria for suspicious for AMR, and 2 were indeterminate for AMR. We further assessed the clinicopathologic characteristics of these 7 patients. All 7 patients had at least 1 biopsy with a histopathologic pattern compatible with acute AMR. Additionally, we observed accompanied moderately to markedly dilated portal/central veins and endothelialitis disproportionate to the degree of bile duct injury in all 7 patients; periportal/perivenular hepatocyte necrosis was seen in 6 of 7 patients; and arteritis was seen in 3 of 7 patients. In each case, microvascular C4d deposition was present in at least 1 biopsy. Posttransplant donor specific anti-HLA antibodies were detected in 5 patients. Two of 7 patients were retransplanted, and 2 died after developing refractory AMR. The remaining 5 patients were alive with stable graft function at a median follow-up of 4.1 years. Conclusions. Our data suggest that acute AMR in pediatric liver grafts is rare, can develop late, and may be associated with graft loss or patient death. The recurrent histopathologic findings of moderately to markedly dilated portal/central veins and endothelialitis disproportionate to the degree of bile duct injury are features that appear unique to pediatric acute AMR of liver grafts.

[1]  Hao-dong Xu,et al.  Immunostaining Patterns of Posttransplant Liver Biopsies Using 2 Anti-C4d Antibodies. , 2020 .

[2]  Jinson J. Erinjeri,et al.  Society of pediatric liver transplantation: Current registry status 2011‐2018 , 2020, Pediatric transplantation.

[3]  T. Schiano,et al.  Recurrent Idiopathic Liver Allograft Failure. , 2019, American journal of clinical pathology.

[4]  A. Israni,et al.  OPTN/SRTR 2016 Annual Data Report: Liver , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  N. Kamar,et al.  Histological long‐term outcomes from acute antibody‐mediated rejection following ABO‐compatible liver transplantation , 2017, Journal of gastroenterology and hepatology.

[6]  B. Naini,et al.  Acute antibody‐mediated rejection in ABO‐compatible pediatric liver transplant recipients: case series and review of the literature , 2017, Pediatric transplantation.

[7]  E. Furth,et al.  2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody‐Mediated Rejection , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  M. L. de la Mata,et al.  Biopsy‐proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: a systematic review and critical appraisal , 2016, Transplant international : official journal of the European Society for Organ Transplantation.

[9]  I. Bilbao,et al.  Acute Antibody-Mediated Rejection as Cause of Late Liver Allograft Failure: A Case Report. , 2015, Transplantation proceedings.

[10]  B. Nashan,et al.  Long-term Clinical Relevance of De Novo Donor-Specific Antibodies After Pediatric Liver Transplantation , 2015, Transplantation.

[11]  E. Reed,et al.  Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation , 2015, Transplantation.

[12]  A. Demetris,et al.  ABO-compatible liver allograft antibody-mediated rejection: an update , 2015, Current opinion in organ transplantation.

[13]  L. D’Albuquerque,et al.  Quantification of C4d deposition and hepatitis C virus RNA in tissue in cases of graft rejection and hepatitis C recurrence after liver transplantation , 2015, Memorias do Instituto Oswaldo Cruz.

[14]  G. Klintmalm,et al.  Acute liver allograft antibody‐mediated rejection: An inter‐institutional study of significant histopathological features , 2014, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[15]  L. Rostaing,et al.  Prevalence, Incidence and Risk Factors for Donor‐Specific Anti‐HLA Antibodies in Maintenance Liver Transplant Patients , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  I. Jankowska,et al.  Antibody-mediated rejection in pediatric liver transplant recipients. , 2014, Annals of transplantation.

[17]  S. Uemoto,et al.  Application of complement component 4d immunohistochemistry to ABO‐compatible and ABO‐incompatible liver transplantation , 2014, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[18]  G. Klintmalm,et al.  De Novo Donor‐Specific HLA Antibodies Decrease Patient and Graft Survival in Liver Transplant Recipients , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  G. Klintmalm,et al.  Bortezomib for Acute Antibody‐Mediated Rejection in Liver Transplantation , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  S. Hübscher Antibody-mediated rejection in the liver allograft , 2012, Current opinion in organ transplantation.

[21]  W-C Lee,et al.  Bortezomib is effective to treat acute humoral rejection after liver transplantation. , 2012, Transplantation proceedings.

[22]  A. Ormsby,et al.  Significance of complement split product C4d in ABO-compatible liver allograft: diagnosing utility in acute antibody mediated rejection. , 2012, Transplant immunology.

[23]  Tse-Ching Chen,et al.  Clinical perspective of acute humoral rejection after blood type-compatible liver transplantation. , 2011, Transplantation.

[24]  S. Hübscher,et al.  Late humoral rejection in a compliant ABO-compatible liver transplant recipient. , 2006, Transplantation.